These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Future supply chains enabled by continuous processing--opportunities and challenges. May 20-21, 2014 Continuous Manufacturing Symposium. Srai JS; Badman C; Krumme M; Futran M; Johnston C J Pharm Sci; 2015 Mar; 104(3):840-9. PubMed ID: 25631279 [TBL] [Abstract][Full Text] [Related]
24. The integration of process analytical technologies, concurrent validation, and parametric release programs in aseptic processing: Parenteral Drug Association. Korczynski MS PDA J Pharm Sci Technol; 2004; 58(4):181-91. PubMed ID: 15368988 [TBL] [Abstract][Full Text] [Related]
25. Achieving continuous manufacturing for final dosage formation: challenges and how to meet them. May 20-21, 2014 Continuous Manufacturing Symposium. Byrn S; Futran M; Thomas H; Jayjock E; Maron N; Meyer RF; Myerson AS; Thien MP; Trout BL J Pharm Sci; 2015 Mar; 104(3):792-802. PubMed ID: 25501530 [TBL] [Abstract][Full Text] [Related]
26. Toward Higher QA: From Parametric Release of Sterile Parenteral Products to PAT for Other Pharmaceutical Dosage Forms. Hock SC; Constance NX; Wah CL PDA J Pharm Sci Technol; 2012; 66(4):371-91. PubMed ID: 22767885 [TBL] [Abstract][Full Text] [Related]
27. Excipient variability and its impact on dosage form functionality. Dave VS; Saoji SD; Raut NA; Haware RV J Pharm Sci; 2015 Mar; 104(3):906-15. PubMed ID: 25561249 [TBL] [Abstract][Full Text] [Related]
28. Additive Manufacturing with 3D Printing: Progress from Bench to Bedside. Rahman Z; Barakh Ali SF; Ozkan T; Charoo NA; Reddy IK; Khan MA AAPS J; 2018 Sep; 20(6):101. PubMed ID: 30209693 [TBL] [Abstract][Full Text] [Related]
29. [Methodology and application of process analytical technology (PAT) for traditional Chinese medicine manufacturing:a review]. Xiong HS; Zhang Q; Zhang SN; Cai JY; Su J; Zhu YH; Yan KJ Zhongguo Zhong Yao Za Zhi; 2023 Jan; 48(1):22-29. PubMed ID: 36725254 [TBL] [Abstract][Full Text] [Related]
30. Strategic funding priorities in the pharmaceutical sciences allied to Quality by Design (QbD) and Process Analytical Technology (PAT). Aksu B; De Beer T; Folestad S; Ketolainen J; Lindén H; Lopes JA; de Matas M; Oostra W; Rantanen J; Weimer M Eur J Pharm Sci; 2012 Sep; 47(2):402-5. PubMed ID: 22749874 [TBL] [Abstract][Full Text] [Related]
32. The development and validation of a quality by design based process analytical tool for the inline quantification of Ramipril during hot-melt extrusion. Dadou SM; Senta-Loys Z; Almajaan A; Li S; Jones DS; Healy AM; Tian Y; Andrews GP Int J Pharm; 2020 Jun; 584():119382. PubMed ID: 32360547 [TBL] [Abstract][Full Text] [Related]
33. System-wide hybrid MPC-PID control of a continuous pharmaceutical tablet manufacturing process via direct compaction. Singh R; Ierapetritou M; Ramachandran R Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1164-82. PubMed ID: 23523542 [TBL] [Abstract][Full Text] [Related]
34. A Review of PAT Strategies in Secondary Solid Oral Dosage Manufacturing of Small Molecules. Laske S; Paudel A; Scheibelhofer O; J Pharm Sci; 2017 Mar; 106(3):667-712. PubMed ID: 28017464 [TBL] [Abstract][Full Text] [Related]
35. Understanding Quality Paradigm Shifts in the Evolving Pharmaceutical Landscape: Perspectives from the USP Quality Advisory Group. Weitzel J; Pappa H; Banik GM; Barker AR; Bladen E; Chirmule N; DeFeo J; Devine J; Emrick S; Hout TK; Levy MS; Mahlangu GN; Rellahan B; Venema J; Workman W AAPS J; 2021 Oct; 23(6):112. PubMed ID: 34654974 [TBL] [Abstract][Full Text] [Related]
36. Top ten hot topics in parenteral science and technology. Akers MJ; Nail SL; Saffell-Clemmer W PDA J Pharm Sci Technol; 2007; 61(5):337-61. PubMed ID: 18047174 [TBL] [Abstract][Full Text] [Related]
37. Melt extrusion with poorly soluble drugs - An integrated review. Repka MA; Bandari S; Kallakunta VR; Vo AQ; McFall H; Pimparade MB; Bhagurkar AM Int J Pharm; 2018 Jan; 535(1-2):68-85. PubMed ID: 29102700 [TBL] [Abstract][Full Text] [Related]
38. Analytical procedure validation and the quality by design paradigm. Rozet E; Lebrun P; Michiels JF; Sondag P; Scherder T; Boulanger B J Biopharm Stat; 2015; 25(2):260-8. PubMed ID: 25357001 [TBL] [Abstract][Full Text] [Related]
39. Potential of Continuous Manufacturing for Liposomal Drug Products. Worsham RD; Thomas V; Farid SS Biotechnol J; 2019 Feb; 14(2):e1700740. PubMed ID: 29781114 [TBL] [Abstract][Full Text] [Related]
40. Statistical thinking and knowledge management for quality-driven design and manufacturing in pharmaceuticals. Korakianiti E; Rekkas D Pharm Res; 2011 Jul; 28(7):1465-79. PubMed ID: 21161338 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]